Urgent.News

What's breaking now, across thousands of outlets.

More in Business

Alteogen Signs Up to $3.22 Billion Licensing Deal With Novartis

Alteogen has secured a landmark licensing deal with global pharmaceutical giant Novartis, underscoring the global competitiveness of its proprietary platform technology for converting intravenous…

  • Alteogen signs $3.22B licensing deal with Novartis on September 2
  • Novartis gets exclusive rights to develop SC versions of biologics using ALT-B4 platform
  • Deal could bring up to $3.22B to Alteogen, with royalties on net sales

More from Wednesday 2 September →